CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
People›
Christopher J. Larson
AddedMar 31, 2024
UpdatedOct 13, 2026
Christopher J. Larson

Christopher J. Larson

Founder, Vasa Therapeutics

Christopher J. Larson's Career

Vasa Therapeutics

Vasa Therapeutics

Seed$8.3MSan Diego, CA, US
Board Member· Board
Founder

Similar to Vasa Therapeutics

TheraVascTheraVascCleveland, OH, USDrugs, Pharmaceuticalsest. 2009TheraVascCleveland, OH, US · est. 2009

TheraVasc Inc., a US pharmaceutical company, specializes in drugs for vascular diseases, particularly peripheral artery disease.

Public · $3.4M5
Vivasc TherapeuticsVivasc TherapeuticsPittsburgh, PA, USDrug Developmentest. 2019Vivasc TherapeuticsPittsburgh, PA, US · est. 2019

Vivasc Therapeutics: Pioneering pre-clinical cardiac drug development and AFiB solutions.

$284k3
Riparian PharmaceuticalsRiparian PharmaceuticalsAllston-Brighton, MA, USMedical Therapiesest. 2012Riparian PharmaceuticalsAllston-Brighton, MA, US · est. 2012

Riparian Pharmaceuticals, a Boston-based biotech firm, innovates in vascular pathophysiology to treat cardiovascular and inflammatory diseases.

Series A · $3.5M8
VasoRxVasoRxSanta Barbara, CA, USRNA Therapiesest. 2018VasoRxSanta Barbara, CA, US · est. 2018

VasoRx: Pioneering RNA therapies for disease treatment, leveraging MIT and Yale discoveries.

$7.2M5
Selection

Selection

Series A$9.2MSan Diego, CA, US
Board Member· Board

Leadership at Selection

Andreas KlostermannAndreas KlostermannFounder
Antonius SchuhAntonius SchuhCEO

Similar to Selection

Tavotek BiotherapeuticsTavotek BiotherapeuticsGwynedd, PA, USBiopharmaceuticals, Therapeuticsest. 2019Tavotek BiotherapeuticsGwynedd, PA, US · est. 2019

Tavotek: A biopharmaceutical company innovating therapies for oncology and autoimmune diseases.

Series B · $55M24
AsclepiX TherapeuticsAsclepiX TherapeuticsBaltimore, MD, USPeptide Therapeuticsest. 2011AsclepiX TherapeuticsBaltimore, MD, US · est. 2011

US-based AsclepiX Therapeutics innovates retinal disease and cancer treatments through novel peptide development.

Series A · $50M16
TolerionTolerionSouth San Francisco, CA, USBiotherapeuticsest. 2001TolerionSouth San Francisco, CA, US · est. 2001

Tolerion: A bio-therapeutic company engineering solutions for autoimmune diseases since 2001.

Public · $43M30
PeptiMedPeptiMedMadison, WI, USTherapeutic Drugsest. 2012PeptiMedMadison, WI, US · est. 2012

PeptiMed, Inc.: A biotech firm developing targeted therapeutic drugs for advanced cancers in the US.

Seed · $500k6

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

People Similar to Christopher J. Larson

Daniel G. AndersonDaniel G. AndersonBoard Member · VasoRxRobert LangerRobert LangerBoard Member · VasoRxMichael SimonsMichael SimonsBoard Member · VasoRxKrisztina ZseboKrisztina ZseboCo-Founder · VasoRxCarter CliffCarter CliffCo-Founder · Dianomi TherapeuticsTony GiordanoTony GiordanoFounder · TheraVascJ. Anthony WareJ. Anthony WareBoard Member · AnaptysBioSandra ShotwellSandra ShotwellBoard Member · Elex Biotech